Oclaiz (octreotide subcutaneous depot) / Camurus 
Welcome,         Profile    Billing    Logout  
 22 Diseases   3 Trials   3 Trials   20 News 
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus, Signifor (pasireotide) / Recordati, paltusotine (CRN00808) / Crinetics
    Review, Journal:  The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives. (Pubmed Central) -  Feb 1, 2025   
    Octreotide and lanreotide appear to be clinically interchangeable, and no signs of superiority of one agent over the other has been observed so far. Whether SSAs may be exploited in the maintenance setting following more aggressive treatments, whether continuing SSAs beyond-progression after first-line therapy could be an effective treatment strategy, and whether new-generation SSAs such as pasireotide could overcome resistance to established SSAs are key areas of investigation.
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Trial completion date, Trial primary completion date:  SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) -  Dec 13, 2024   
    P3,  N=332, Active, not recruiting, 
    Whether SSAs may be exploited in the maintenance setting following more aggressive treatments, whether continuing SSAs beyond-progression after first-line therapy could be an effective treatment strategy, and whether new-generation SSAs such as pasireotide could overcome resistance to established SSAs are key areas of investigation. Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    A RANDOMIZED PHASE 3 TRIAL TO ASSESS EFFICACY AND SAFETY OF A NOVEL FORMULATION OF OCTREOTIDE SUBCUTANEOUS DEPOT IN PATIENTS WITH ACROMEGALY (Umm Al Quwain hall) -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_595;    
    P3
    In this phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT04076462), patients on stable treatment with octreotide LAR or lanreotide autogel, and with normal IGF-1 levels at screening, were randomized 2:1 to once-monthly CAM2029 20 mg or placebo for 24 weeks. CAM2029 treatment resulted in robust biochemical control superior to placebo, substantially improved PROs compared to baseline SoC and placebo, and a safety profile consistent with SoC somatostatin receptor ligand treatments, demonstrating the potential of CAM2029 as an alternative to SoC acromegaly treatments that addresses unmet patient needs.
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Enrollment closed:  POSITANO: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (clinicaltrials.gov) -  Feb 14, 2024   
    P2/3,  N=71, Active, not recruiting, 
    CAM2029 treatment resulted in robust biochemical control superior to placebo, substantially improved PROs compared to baseline SoC and placebo, and a safety profile consistent with SoC somatostatin receptor ligand treatments, demonstrating the potential of CAM2029 as an alternative to SoC acromegaly treatments that addresses unmet patient needs. Recruiting --> Active, not recruiting
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Enrollment closed, Trial completion date, Trial primary completion date:  A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Jun 22, 2023   
    P3,  N=135, Active, not recruiting, 
    Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    Trial completion date, Trial primary completion date:  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Jul 18, 2022   
    P3,  N=78, Recruiting, 
    Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Feb 2023 --> Sep 2023 Trial completion date: Oct 2022 --> May 2023 | Trial primary completion date: Sep 2022 --> Apr 2023
  • ||||||||||  octreotide chloride FluidCrystal Injection depot (CAM2029) / Novartis, Signifor (pasireotide) / Recordati
    Clinical, Journal:  Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers. (Pubmed Central) -  Mar 24, 2022   
    This novel head-to-head superiority trial is anticipated to demonstrate the potential benefits of CAM2029 as a first line-therapy in patients with well-differentiated GEP-NETs. Combined low doses of pasireotide LAR (5 mg) and octreotide LAR (10-30 mg) provided greater suppression of IGF-I than either single agent and did not increase blood glucose or incidence of AEs versus either agent alone.
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Trial completion date, Trial primary completion date:  A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Nov 9, 2021   
    P3,  N=140, Recruiting, 
    Combined low doses of pasireotide LAR (5 mg) and octreotide LAR (10-30 mg) provided greater suppression of IGF-I than either single agent and did not increase blood glucose or incidence of AEs versus either agent alone. Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Feb 2023
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    Trial completion date, Trial primary completion date:  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Nov 9, 2021   
    P3,  N=78, Recruiting, 
    Trial completion date: Apr 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Feb 2023 Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Trial completion date, Trial initiation date, Trial primary completion date:  A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Sep 17, 2020   
    P3,  N=140, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Sep 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Oct 2019 | Trial primary completion date: Aug 2021 --> Mar 2022
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    Trial completion date, Trial primary completion date:  A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) -  Sep 17, 2020   
    P3,  N=78, Recruiting, 
    Trial completion date: Sep 2021 --> Apr 2022 | Initiation date: Jul 2020 --> Oct 2019 | Trial primary completion date: Aug 2021 --> Mar 2022 Trial completion date: Feb 2021 --> Oct 2021 | Trial primary completion date: Jan 2021 --> Sep 2021